Melanoma News and Research RSS Feed - Melanoma News and Research

Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

EKF Diagnostics, the global diagnostics company, announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK, have continued to confirm the effectiveness of its PointMan DNA enrichment technology for isolating and characterizing low-level DNA mutations in blood. [More]
Researchers receive nearly $3.6 million to create new National Clinical Trials Network

Researchers receive nearly $3.6 million to create new National Clinical Trials Network

A team of physician-researchers from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has received nearly $3.6 million over the next five years in a cooperative agreement with the National Institutes of Health (NIH) to establish a Network Lead Academic Participating Site (NLAPS). [More]
Salk scientists identify gene that fights metastasis of common lung cancer

Salk scientists identify gene that fights metastasis of common lung cancer

Scientists at the Salk Institute have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world's deadliest cancers. [More]
Study attempts to link sun exposure and low vitamin D levels with increased death rate

Study attempts to link sun exposure and low vitamin D levels with increased death rate

Recently, a study in the Journal of Internal Medicine suggested that women who avoid sun exposure are twice as likely to die as compared to those who receive sun exposure. [More]
Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Eli Lilly and Company and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. [More]
Engineering single-celled parasite in cat's intestine as cancer vaccine

Engineering single-celled parasite in cat's intestine as cancer vaccine

Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 million of which are Americans. [More]
New study reveals how genetic defect may make people more susceptible to developing melanoma

New study reveals how genetic defect may make people more susceptible to developing melanoma

A new study by University of Kentucky researchers shows how a genetic defect in a specific hormonal pathway may make people more susceptible to developing melanoma, the deadliest type of skin cancer. [More]
Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer). [More]
New role for cholesterol in activation of cellular signaling pathway that linked to cancer

New role for cholesterol in activation of cellular signaling pathway that linked to cancer

Everyone knows that cholesterol, at least the bad kind, can cause heart disease and hardening of the arteries. Now, researchers at the University of Illinois at Chicago describe a new role for cholesterol in the activation of a cellular signaling pathway that has been linked to cancer. [More]
Sunscreens do not protect totally against development of skin cancer, shows study

Sunscreens do not protect totally against development of skin cancer, shows study

The researcher at the Neurosciences Institute, Joint Center of the University Miguel Hernández (UMH) in Elche and the Higher Council for Scientific Research (CSIC), Berta López Sánchez-Laorden co-authored a study that concluded that sunscreens do not protect totally against the development of skin cancer. [More]
Twitter should be better utilized to convey public health messages, say researchers

Twitter should be better utilized to convey public health messages, say researchers

Twitter and other social media should be better utilized to convey public health messages, especially to young adults, according to a new analysis by researchers at UC San Francisco. [More]
NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics launches 23 NGS-based NeoTYPE Cancer Profiles

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS). [More]
Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]

Lung cancer and melanoma funders form first-ever research collaboration

LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical treatment improves survival for metastatic melanoma patients whose disease is limited to the liver

Surgical resection markedly improves survival among metastatic melanoma patients whose disease is isolated to a few areas in the liver, according to new study findings published in the July issue of the Journal of the American College of Surgeons. [More]
New approach may help develop more effective immunotherapy for metastatic melanoma

New approach may help develop more effective immunotherapy for metastatic melanoma

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. [More]
Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment. [More]
EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma. [More]